Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 446

1.

T cell large granular lymphocyte leukemia and chronic NK lymphocytosis.

Barilà G, Calabretto G, Teramo A, Vicenzetto C, Gasparini VR, Semenzato G, Zambello R.

Best Pract Res Clin Haematol. 2019 Sep;32(3):207-216. doi: 10.1016/j.beha.2019.06.006. Epub 2019 Jun 22. Review.

PMID:
31585621
2.

Comparison of Presepsin, Procalcitonin, Interleukin-8 and C-Reactive Protein in Predicting Bacteraemia in Febrile Neutropenic Adult Patients with Haematological Malignancies.

Kostic I, Gurrieri C, Piva E, Semenzato G, Plebani M, Caputo I, Vianello F.

Mediterr J Hematol Infect Dis. 2019 Sep 1;11(1):e2019047. doi: 10.4084/MJHID.2019.047. eCollection 2019.

3.

Identification of a miR-146b-FasL axis in the development of neutropenia in T large granular lymphocyte leukemia.

Mariotti B, Calabretto G, Rossato M, Teramo A, Castellucci M, Barilà G, Leoncin M, Vicenzetto C, Facco M, Semenzato G, Bazzoni F, Zambello R.

Haematologica. 2019 Aug 29. pii: haematol.2019.225060. doi: 10.3324/haematol.2019.225060. [Epub ahead of print]

4.

Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.

Visentin A, Facco M, Gurrieri C, Pagnin E, Martini V, Imbergamo S, Frezzato F, Trimarco V, Severin F, Raggi F, Scomazzon E, Pravato S, Piazza F, Semenzato G, Trentin L.

Clin Lymphoma Myeloma Leuk. 2019 Mar 11. pii: S2152-2650(18)31763-4. doi: 10.1016/j.clml.2019.03.002. [Epub ahead of print]

PMID:
31371221
5.

A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia.

Visentin A, Deodato M, Mauro FR, Autore F, Reda G, Vitale C, Molica S, Rigolin GM, Piazza F, Cesini L, Tedeschi A, Laurenti L, Cassin R, Coscia M, Cuneo A, Foà R, Semenzato G, Trentin L.

Hematol Oncol. 2019 Jul 23. doi: 10.1002/hon.2655. [Epub ahead of print] No abstract available.

PMID:
31335982
6.

The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia.

Visentin A, Bonaldi L, Rigolin GM, Mauro FR, Martines A, Frezzato F, Imbergamo S, Scomazzon E, Pravato S, Bardi MA, Cavallari M, Volta E, Cavazzini F, Nanni M, Del Giudice I, Facco M, Guarini A, Semenzato G, Foà R, Cuneo A, Trentin L.

Br J Cancer. 2019 Jul;121(2):150-156. doi: 10.1038/s41416-019-0502-x. Epub 2019 Jun 18.

PMID:
31209327
7.

Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma.

Carrino M, Quotti Tubi L, Fregnani A, Canovas Nunes S, Barilà G, Trentin L, Zambello R, Semenzato G, Manni S, Piazza F.

Cell Death Discov. 2019 May 21;5:98. doi: 10.1038/s41420-019-0179-1. eCollection 2019.

8.

HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia.

Frezzato F, Raggi F, Martini V, Severin F, Trimarco V, Visentin A, Scomazzon E, Accordi B, Bresolin S, Piazza F, Facco M, Basso G, Semenzato G, Trentin L.

Int J Cancer. 2019 Dec 1;145(11):3089-3100. doi: 10.1002/ijc.32383. Epub 2019 May 15.

PMID:
31044428
9.

Severe infections unrelated to neutropenia impact on overall survival in multiple myeloma patients: results of a single centre cohort study.

Barilà G, Compagno N, Liço A, Berno T, Bonaldi L, Teramo A, Manni S, Branca A, Frigo AC, Cinetto F, Piazza F, Semenzato G, Zambello R.

Br J Haematol. 2019 Aug;186(3):e13-e17. doi: 10.1111/bjh.15849. Epub 2019 Mar 10. No abstract available.

PMID:
30854624
10.

p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.

Patrussi L, Capitani N, Ulivieri C, Manganaro N, Granai M, Cattaneo F, Kabanova A, Mundo L, Gobessi S, Frezzato F, Visentin A, Finetti F, Pelicci PG, D'Elios MM, Trentin L, Semenzato G, Leoncini L, Efremov DG, Baldari CT.

Haematologica. 2019 Oct;104(10):2040-2052. doi: 10.3324/haematol.2018.209981. Epub 2019 Feb 28.

11.

Bortezomib-based regimens in patients with POEMS syndrome: a case series in newly diagnosed and relapsed patients.

Riva M, Lessi F, Berno T, Visentin A, Campagnolo M, Semenzato G, Adami F, Briani C.

Leuk Lymphoma. 2019 Aug;60(8):2067-2070. doi: 10.1080/10428194.2018.1564048. Epub 2019 Jan 22. No abstract available.

PMID:
30668203
12.

Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI.

Zambello R, Crimì F, Lico A, Barilà G, Branca A, Guolo A, Varin C, Vezzaro R, Checuz L, Scapin V, Berno T, Pizzi M, Ponzoni A, De Biasi E, Vio S, Semenzato G, Zucchetta P, Lacognata C.

Ann Hematol. 2019 Mar;98(3):679-689. doi: 10.1007/s00277-018-3555-7. Epub 2018 Dec 11.

13.

Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.

Filì C, Candoni A, Zannier ME, Olivieri J, Imbergamo S, Caizzi M, Nadali G, Di Bona E, Ermacora A, Gottardi M, Facchinelli D, Ciancia R, Lazzarotto D, Dubbini MV, Festini G, Gherlinzoni F, Michieli MG, Semenzato G, Fanin R.

Leuk Res. 2019 Jan;76:33-38. doi: 10.1016/j.leukres.2018.11.015. Epub 2018 Nov 28.

PMID:
30529681
14.

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.

Palandri F, Palumbo GA, Iurlo A, Polverelli N, Benevolo G, Breccia M, Abruzzese E, Tiribelli M, Bonifacio M, Tieghi A, Isidori A, Martino B, Sgherza N, D'Adda M, Bergamaschi M, Crugnola M, Cavazzini F, Bosi C, Binotto G, Auteri G, Latagliata R, Ibatici A, Scaffidi L, Penna D, Cattaneo D, Soci F, Trawinska M, Russo D, Cuneo A, Semenzato G, Di Raimondo F, Aversa F, Lemoli RM, Heidel F, Reggiani MLB, Bartoletti D, Cavo M, Catani L, Vianelli N.

Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.

PMID:
30502854
15.

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.

Breccia M, Bartoletti D, Bonifacio M, Palumbo GA, Polverelli N, Abruzzese E, Bergamaschi M, Tieghi A, Tiribelli M, Iurlo A, Cavazzini F, Sgherza N, Binotto G, Isidori A, D'Adda M, Crugnola M, Bosi C, Heidel F, Molica M, Scaffidi L, Cattaneo D, Latagliata R, Auteri G, Lemoli RM, Fanin R, Russo D, Aversa F, Cuneo A, Semenzato G, Catani L, Cavo M, Vianelli N, Foà R, Palandri F.

Ann Hematol. 2019 Apr;98(4):889-896. doi: 10.1007/s00277-018-3569-1. Epub 2018 Dec 4.

PMID:
30515542
16.

Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma.

Pizzi M, Trentin L, Visentin A, Saraggi D, Martini V, Guzzardo V, Righi S, Frezzato F, Piazza F, Sabattini E, Semenzato G, Rugge M.

Hum Pathol. 2019 Mar;85:251-259. doi: 10.1016/j.humpath.2018.10.038. Epub 2018 Nov 17.

PMID:
30458196
17.

Relevance of antiphospholipid antibody profile in the clinical outcome of ITP: a single-centre study.

Frison L, Lombardi A, Caputo I, Semenzato G, Fabris F, Vianello F.

Hematology. 2019 Dec;24(1):134-138. doi: 10.1080/10245332.2018.1532649. Epub 2018 Oct 25.

PMID:
30355275
18.

Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL.

Pagano MA, Tibaldi E, Molino P, Frezzato F, Trimarco V, Facco M, Zagotto G, Ribaudo G, Leanza L, Peruzzo R, Szabò I, Visentin A, Frasson M, Semenzato G, Trentin L, Brunati AM.

Leukemia. 2019 May;33(5):1148-1160. doi: 10.1038/s41375-018-0288-5. Epub 2018 Oct 23.

PMID:
30353029
19.

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients.

Palandri F, Palumbo GA, Bonifacio M, Breccia M, Latagliata R, Martino B, Polverelli N, Abruzzese E, Tiribelli M, Nicolosi M, Bergamaschi M, Tieghi A, Iurlo A, Sgherza N, Cavazzini F, Isidori A, Binotto G, Ibatici A, Crugnola M, Heidel F, Bosi C, Bartoletti D, Auteri G, Catani L, Cuneo A, Aversa F, Semenzato G, Cavo M, Vianelli N, Benevolo G.

Leuk Res. 2018 Nov;74:86-88. doi: 10.1016/j.leukres.2018.10.001. Epub 2018 Oct 5. No abstract available.

PMID:
30321784
20.

Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy.

Bonifacio M, Scaffidi L, Binotto G, Miggiano MC, Danini M, Minotto C, Griguolo D, Marin L, Frison L, D'Amore F, Basso M, Sartori R, Tinelli M, Stulle M, Fortuna S, Bonalumi A, Bertoldero G, De Biasi E, Ruggeri M, Semenzato G, Fanin R, Pizzolo G, Krampera M, Tiribelli M.

Leuk Res. 2018 Nov;74:75-79. doi: 10.1016/j.leukres.2018.09.018. Epub 2018 Oct 2.

PMID:
30308414
21.

Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemia.

Martini V, Frezzato F, Severin F, Raggi F, Trimarco V, Martinello L, Molfetta R, Visentin A, Facco M, Semenzato G, Paolini R, Trentin L.

Oncotarget. 2018 Aug 14;9(63):32219-32231. doi: 10.18632/oncotarget.25951. eCollection 2018 Aug 14.

22.

Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases.

Visentin A, Campello E, Scomazzon E, Spiezia L, Imbergamo S, Pravato S, Piazza F, Semenzato G, Simioni P, Trentin L.

Hematol Oncol. 2018 Dec;36(5):801-803. doi: 10.1002/hon.2545. Epub 2018 Sep 6. No abstract available.

PMID:
30110712
23.

Possible neuroleukemiosis in two patients with acute myeloid leukemia in complete bone marrow remission.

Kostic I, Ruiz M, Branca A, Nabergoj M, Piazza F, Semenzato G, Gurrieri C, Briani C.

J Neurol Sci. 2018 Sep 15;392:63-64. doi: 10.1016/j.jns.2018.06.029. Epub 2018 Jun 30. No abstract available.

PMID:
30049661
24.

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.

Palandri F, Catani L, Bonifacio M, Benevolo G, Heidel F, Palumbo GA, Crugnola M, Abruzzese E, Bartoletti D, Polverelli N, Bergamaschi M, Tiribelli M, Iurlo A, Breccia M, Cavazzini F, Tieghi A, Binotto G, Isidori A, Martino B, D'Adda M, Bosi C, Sabattini E, Vitolo U, Aversa F, Ibatici A, Lemoli RM, Sgherza N, Cuneo A, Martinelli G, Semenzato G, Cavo M, Vianelli N, Sapienza MR, Latagliata R.

Br J Haematol. 2018 Oct;183(1):35-46. doi: 10.1111/bjh.15497. Epub 2018 Jul 16.

PMID:
30010187
25.

BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.

Visentin A, Imbergamo S, Scomazzon E, Pravato S, Frezzato F, Bonaldi L, Pizzi M, Vio S, Gregianin M, Burei M, Facco M, Semenzato G, Piazza F, Trentin L.

Br J Haematol. 2019 Apr;185(1):193-197. doi: 10.1111/bjh.15440. Epub 2018 Jul 5. No abstract available.

PMID:
29974955
26.

Benign TdT-positive cells in pediatric and adult lymph nodes: a potential diagnostic pitfall.

Pizzi M, Brignola S, Righi S, Agostinelli C, Bertuzzi C, Pillon M, Semenzato G, Rugge M, Sabattini E.

Hum Pathol. 2018 Nov;81:131-137. doi: 10.1016/j.humpath.2018.06.027. Epub 2018 Jun 30.

PMID:
29969607
27.

Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation.

Barilà G, Teramo A, Calabretto G, Ercolin C, Boscaro E, Trimarco V, Carraro S, Leoncin M, Vicenzetto C, Cabrelle A, Facco M, Piazza F, Semenzato G, Zambello R.

Blood Cancer J. 2018 Jun 5;8(6):51. doi: 10.1038/s41408-018-0088-1. No abstract available.

28.

Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance.

Manni S, Carrino M, Semenzato G, Piazza F.

Int J Mol Sci. 2018 May 18;19(5). pii: E1512. doi: 10.3390/ijms19051512. Review.

29.

Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.

Scapinello G, Pizzi M, Vio S, Nabergoj M, Visentin A, Martines A, Bonaldi L, Trentin L, Semenzato G, Piazza F.

Ann Hematol. 2018 Oct;97(10):2001-2003. doi: 10.1007/s00277-018-3351-4. Epub 2018 May 4. No abstract available.

PMID:
29728736
30.

In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.

Rigolin GM, Saccenti E, Guardalben E, Cavallari M, Formigaro L, Zagatti B, Visentin A, Mauro FR, Lista E, Bassi C, Lupini L, Quaglia FM, Urso A, Bardi MA, Bonaldi L, Volta E, Tammiso E, Ilari C, Cafforio L, Melandri A, Cavazzini F, Negrini M, Semenzato G, Trentin L, Foà R, Cuneo A.

Br J Haematol. 2018 Apr;181(2):229-233. doi: 10.1111/bjh.15174. Epub 2018 Apr 2.

PMID:
29611195
31.

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients.

Tiribelli M, Bonifacio M, Binotto G, Iurlo A, Cibien F, Maino E, Guella A, Festini G, Minotto C, De Biasi E, De Marchi F, Scaffidi L, Frison L, Bucelli C, Medeot M, Calistri E, Sancetta R, Stulle M, Orofino N, Krampera M, Gherlinzoni F, Semenzato G, Pizzolo G, Ambrosetti A, Fanin R.

Oncotarget. 2018 Feb 12;9(18):14219-14227. doi: 10.18632/oncotarget.24478. eCollection 2018 Mar 6.

32.

The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma.

Canovas Nunes S, Manzoni M, Pizzi M, Mandato E, Carrino M, Quotti Tubi L, Zambello R, Adami F, Visentin A, Barilà G, Trentin L, Manni S, Neri A, Semenzato G, Piazza F.

Blood Cancer J. 2018 Feb 13;8(2):20. doi: 10.1038/s41408-018-0053-z.

33.

p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes.

Patrussi L, Capitani N, Cattaneo F, Manganaro N, Gamberucci A, Frezzato F, Martini V, Visentin A, Pelicci PG, D'Elios MM, Trentin L, Semenzato G, Baldari CT.

Oncogene. 2018 Mar;37(11):1534-1550. doi: 10.1038/s41388-017-0066-2. Epub 2018 Jan 12.

PMID:
29326436
34.

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases.

Visentin A, Imbergamo S, Frezzato F, Pizzi M, Bertorelle R, Scomazzon E, Berno T, Riva M, Piva E, Facco M, Piazza F, Semenzato G, Trentin L.

Oncotarget. 2017 Sep 28;8(66):110727-110731. doi: 10.18632/oncotarget.21304. eCollection 2017 Dec 15.

35.

STAT3 mutation impacts biological and clinical features of T-LGL leukemia.

Teramo A, Barilà G, Calabretto G, Ercolin C, Lamy T, Moignet A, Roussel M, Pastoret C, Leoncin M, Gattazzo C, Cabrelle A, Boscaro E, Teolato S, Pagnin E, Berno T, De March E, Facco M, Piazza F, Trentin L, Semenzato G, Zambello R.

Oncotarget. 2017 Jun 27;8(37):61876-61889. doi: 10.18632/oncotarget.18711. eCollection 2017 Sep 22.

36.

Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia.

Visentin A, Briani C, Imbergamo S, Frezzato F, Angelini A, Fedrigo M, Cacciavillani M, Altinier S, Piazza F, Semenzato G, Adami F, Trentin L.

Hematol Oncol. 2018 Feb;36(1):366-369. doi: 10.1002/hon.2480. Epub 2017 Oct 3.

PMID:
28971495
37.

Diagnostic and prognostic value of low percentage of glycosylated ferritin in acquired hemophagocytic lymphohistiocytosis: A single-center study.

Nabergoj M, Marinova M, Binotto G, Brugnaro L, Zaninotto M, Plebani M, Semenzato G, Vianello F.

Int J Lab Hematol. 2017 Dec;39(6):620-624. doi: 10.1111/ijlh.12713. Epub 2017 Jul 18.

PMID:
28722256
38.

Aberrant expression of CD10 and BCL6 in mantle cell lymphoma.

Pizzi M, Agostinelli C, Righi S, Gazzola A, Mannu C, Galuppini F, Fassan M, Visentin A, Piazza F, Semenzato GC, Rugge M, Sabattini E.

Histopathology. 2017 Nov;71(5):769-777. doi: 10.1111/his.13286. Epub 2017 Aug 8.

PMID:
28628241
39.

Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells.

Tibaldi E, Pagano MA, Frezzato F, Trimarco V, Facco M, Zagotto G, Ribaudo G, Pavan V, Bordin L, Visentin A, Zonta F, Semenzato G, Brunati AM, Trentin L.

Haematologica. 2017 Aug;102(8):1401-1412. doi: 10.3324/haematol.2016.155747. Epub 2017 Jun 15.

40.

CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.

Mandato E, Nunes SC, Zaffino F, Casellato A, Macaccaro P, Tubi LQ, Visentin A, Trentin L, Semenzato G, Piazza F.

Curr Cancer Drug Targets. 2018;18(6):608-616. doi: 10.2174/1568009617666170427110450.

PMID:
28460620
41.

Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.

Martini V, Gattazzo C, Frezzato F, Trimarco V, Pizzi M, Chiodin G, Severin F, Scomazzon E, Guzzardo V, Saraggi D, Raggi F, Martinello L, Facco M, Visentin A, Piazza F, Brunati AM, Semenzato G, Trentin L.

Br J Haematol. 2017 Jul;178(1):81-93. doi: 10.1111/bjh.14642. Epub 2017 Apr 17.

PMID:
28419476
42.

Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo.

Leanza L, Romio M, Becker KA, Azzolini M, Trentin L, Managò A, Venturini E, Zaccagnino A, Mattarei A, Carraretto L, Urbani A, Kadow S, Biasutto L, Martini V, Severin F, Peruzzo R, Trimarco V, Egberts JH, Hauser C, Visentin A, Semenzato G, Kalthoff H, Zoratti M, Gulbins E, Paradisi C, Szabo I.

Cancer Cell. 2017 Apr 10;31(4):516-531.e10. doi: 10.1016/j.ccell.2017.03.003.

43.

Role of miR-15a/miR-16-1 and the TP53 axis in regulating telomerase expression in chronic lymphocytic leukemia.

Rampazzo E, Bojnik E, Trentin L, Bonaldi L, Del Bianco P, Frezzato F, Visentin A, Facco M, Semenzato G, De Rossi A.

Haematologica. 2017 Jul;102(7):e253-e256. doi: 10.3324/haematol.2016.157669. Epub 2017 Apr 6. No abstract available.

44.

Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.

Manni S, Carrino M, Manzoni M, Gianesin K, Nunes SC, Costacurta M, Tubi LQ, Macaccaro P, Taiana E, Cabrelle A, Barilà G, Martines A, Zambello R, Bonaldi L, Trentin L, Neri A, Semenzato G, Piazza F.

Oncotarget. 2017 Feb 28;8(9):14604-14619. doi: 10.18632/oncotarget.14654.

45.

Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients.

Visentin A, Imbergamo S, Gurrieri C, Frezzato F, Trimarco V, Martini V, Severin F, Raggi F, Scomazzon E, Facco M, Piazza F, Semenzato G, Trentin L.

Eur J Cancer. 2017 Feb;72:103-111. doi: 10.1016/j.ejca.2016.11.020. Epub 2016 Dec 24.

PMID:
28027513
46.

Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients.

Briani C, Visentin A, Salvalaggio A, Imbergamo S, Piazza F, Cacciavillani M, Campagnolo M, Frezzato F, Semenzato G, Trentin L.

Haematologica. 2017 Apr;102(4):e140-e143. doi: 10.3324/haematol.2016.153064. Epub 2016 Dec 7. No abstract available.

47.

Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment-naïve chronic lymphocytic leukemia.

Cavallini C, Visco C, Putta S, Rossi D, Mimiola E, Purvis N, Lovato O, Perbellini O, Falisi E, Facco M, Trentin L, Romanelli MG, Semenzato G, Ambrosetti A, Gaidano G, Pizzolo G, Cesano A, Scupoli MT.

Haematologica. 2017 Apr;102(4):e144-e147. doi: 10.3324/haematol.2016.154450. Epub 2016 Dec 7. No abstract available.

48.

Profiling B cell chronic lymphocytic leukemia by reverse phase protein array: Focus on apoptotic proteins.

Frezzato F, Accordi B, Trimarco V, Gattazzo C, Martini V, Milani G, Bresolin S, Severin F, Visentin A, Basso G, Semenzato G, Trentin L.

J Leukoc Biol. 2016 Nov;100(5):1061-1070. Epub 2016 Jun 16.

PMID:
27312846
49.

Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia.

Visentin A, Gurrieri C, Imbergamo S, Lessi F, Di Maggio SA, Frezzato F, Adami F, Zambello R, Piazza F, Semenzato G, Trentin L.

Hematol Oncol. 2017 Dec;35(4):925-928. doi: 10.1002/hon.2343. Epub 2016 Sep 19. No abstract available.

PMID:
27641225
50.

A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia.

Laurenzana I, Caivano A, Trino S, De Luca L, La Rocca F, Simeon V, Tintori C, D'Alessio F, Teramo A, Zambello R, Traficante A, Maietti M, Semenzato G, Schenone S, Botta M, Musto P, Del Vecchio L.

Oncotarget. 2016 Oct 4;7(40):65171-65184. doi: 10.18632/oncotarget.11496.

Supplemental Content

Loading ...
Support Center